Advertisement

Topics

PathoGenesis Corporation Company Profile

09:39 EDT 21st September 2018 | BioPortfolio

PathoGenesis Corporation develops and markets novel drugs to treat serious, chronic human infectious diseases where there is a significant need for improved therapy. In December 1997, the U. S. Food and Drug Administration approved ourfirst drug, TOBI (tobramycin solution for inhalation). TOBI is indicated for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. PathoGenesis Corporation began marketing TOBI in 1998 in the U.S., and generated $60.7 million in sales during the year. TOBI was approved for sale in Canada and Argentina in February 1999. PathoGenesis Corporation have filed for regulatory approvals in Europe and Australia. Applications in other countries are pending.

Location

201 Elliott Avenue W. Suite 150
Seattle
Washington
98119
United States of America

Contact

Phone: 206 467 8100
Fax: 206 270 3313


News Articles [149 Associated News Articles listed on BioPortfolio]

TEDDY: More Small Clues to the Pathogenesis of Type 1 Diabetes

Latest TEDDY findings point to childhood infections, in particular gastrointestinal infections, as drivers of islet autoimmunity subtypes in the pathogenesis of type 1 diabetes. Medscape Medical New...

Fatty liver disease pandemic needs 'gold standard' human-relevant research

(Humane Society International) New study calls for human-based tools to unravel the pathogenesis of non-alcoholic steatohepatitis (NASH). The contribution of in silico, in vitro and pathways-based sys...

Orion Corporation: Managers' transactions - Ari Lehtoranta

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Ari Lehtoranta Orion Corporation has received the...

Orion Corporation: Managers' transactions - Timo Maasilta

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Timo Maasilta Orion Corporation has received the ...

Orion Corporation: Managers' transactions - Mikael Silvennoinen

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST              Orion Corporation: Managers' transactions - Mikael Silvennoinen Orio...

Orion Corporation: Managers' transactions - Eija Ronkainen

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST Orion Corporation: Managers' transactions - Eija Ronkainen Orion Corporation has received...

Orion Corporation: Managers' transactions - Sirpa Jalkanen

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Sirpa Jalkanen Orion Corporation has received the ...

Orion Corporation: Managers' transactions - Heikki Westerlund

ORION CORPORATION      MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST              Orion Corporation: Managers' transactions - Heikki Westerlund Orion Co...

PubMed Articles [397 Associated PubMed Articles listed on BioPortfolio]

Pathogenicity-island-encoded regulatory RNAs regulate bacterial virulence and pathogenesis.

Bacterial regulatory RNAs (regRNAs) have been widely studied for decades and shown to be involved in various aspects of bacterial survival, including their virulence and pathogenesis. Recently, many r...

Research advance of microRNA in the pathogenesis of chronic rhinosinusitis.

Chronic rhinosinusitis (CRS) is a common disease of otorhinolaryngology head and neck surgery, manifested as nasal-sinus mucosal chronic inflammation. However, the pathogenesis of CRS is not clear. Th...

Pro-inflammatory role of transient receptor potential canonical channel 6 in the pathogenesis of chronic rhinosinusitis with nasal polyps.

The pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP) has not been fully elucidated. This study sought to explore the role and mechanism of transient receptor potential canonical chann...

Biology of viral satellites and their role in pathogenesis.

Extraviral components that can influence the accumulation and pathogenesis of their associated helper viruses are known as 'satellites'. The maintenance of satellites requires their ability to associa...

Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies.

Recent preclinical studies suggest that dysfunction of gastrointestinal tract may play a role in amyotrophic lateral sclerosis (ALS) pathogenesis through a modification of the gut microbiota brain axi...

Clinical Trials [583 Associated Clinical Trials listed on BioPortfolio]

Adrenal Tumors - Pathogenesis and Therapy

The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenes...

Pathogenesis of Primary Spontaneous Pneumothorax

Primary spontaneous pneumothorax most commonly occurs in young, tall, lean males. The estimated recurrence rate is 23-50% after the first episode and increases to 60% after the second pneu...

Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure

Heart failure (HF) is a continuously growing public health problem. The study aim to provide novel insights into the role of amino acids in pathogenesis of heart failure, to obtain a bette...

HIV Diversity and Pathogenesis in Donor-Recipient Clusters

To assess, in donor-recipient clusters, current models of HIV-1 genetic evolution and pathogenesis, based on the sequence diversity displayed by this lentivirus.

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certa...

Companies [183 Associated Companies listed on BioPortfolio]

PathoGenesis Corporation

PathoGenesis Corporation develops and markets novel drugs to treat serious, chronic human infectious diseases where there is a significant need for improved therapy. In December 1997, the U. S. Food ...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

Bruker Daltonics

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...

NEC Corporation of America

NEC Corporation of America (NEC) is a leading technology integrator providing solutions that improve the way people work and communicate. NEC delivers integrated Solutions for Soc...

Orchestra Therapeutics

Orchestra Therapeutics’ unique approach to controlling autoimmune diseases uses small peptide vaccines that appear to stimulate FOXP3+ Regulatory T-cells; a component of the immune system that is no...

More Information about "PathoGenesis Corporation" on BioPortfolio

We have published hundreds of PathoGenesis Corporation news stories on BioPortfolio along with dozens of PathoGenesis Corporation Clinical Trials and PubMed Articles about PathoGenesis Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PathoGenesis Corporation Companies in our database. You can also find out about relevant PathoGenesis Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record